210 related articles for article (PubMed ID: 25046218)
21. Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors.
Shulman DS; Lee MA; Lehmann LE; Margossian SP
J Pediatr Hematol Oncol; 2016 Nov; 38(8):610-614. PubMed ID: 27403776
[TBL] [Abstract][Full Text] [Related]
22. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.
Lübking A; Dreimane A; Sandin F; Isaksson C; Märkevärn B; Brune M; Ljungman P; Lenhoff S; Stenke L; Höglund M; Richter J; Olsson-Strömberg U
Bone Marrow Transplant; 2019 Nov; 54(11):1764-1774. PubMed ID: 30962502
[TBL] [Abstract][Full Text] [Related]
24. Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.
Kawano N; Kimura S; Miura M; Tochigi T; Nakaike T; Yamashita K; Mashiba K; Kikuchi I; Takahashi N
Int J Hematol; 2021 Oct; 114(4):509-516. PubMed ID: 34406581
[TBL] [Abstract][Full Text] [Related]
25. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
[TBL] [Abstract][Full Text] [Related]
26. Management of chronic myeloid leukemia in blast crisis.
Saußele S; Silver RT
Ann Hematol; 2015 Apr; 94 Suppl 2():S159-65. PubMed ID: 25814082
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults With CML in the TKI Era.
Shimada H; Tanizawa A; Kondo T; Nagamura-Inoue T; Yasui M; Tojo A; Muramatsu H; Eto T; Doki N; Tanaka M; Sato M; Noguchi M; Uchida N; Takahashi Y; Sakata N; Ichinohe T; Hashii Y; Kato K; Atsuta Y; Ohashi K;
Transplant Cell Ther; 2022 Jul; 28(7):376-389. PubMed ID: 35447373
[TBL] [Abstract][Full Text] [Related]
28. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
[TBL] [Abstract][Full Text] [Related]
29. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.
Shanavas M; Messner HA; Kamel-Reid S; Atenafu EG; Gupta V; Kuruvilla J; Kim DD; Uhm J; Lambie A; Ellis L; Lipton JH
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):87-92. PubMed ID: 24252361
[TBL] [Abstract][Full Text] [Related]
30. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
Zhao Y; Wang J; Luo Y; Shi J; Zheng W; Tan Y; Cai Z; Huang H
Ann Hematol; 2017 Aug; 96(8):1353-1360. PubMed ID: 28624905
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy comparison of sequential treatment with first-line administration of second-generation and first-generation tyrosine kinase inhibitors in patients with Ph
Yang F; Cai WZ; Yang XD; Chen SN; Tang XW; Sun AN; Wu DP; Qian WQ; Qiu HY
Zhonghua Xue Ye Xue Za Zhi; 2018 Feb; 39(2):110-115. PubMed ID: 29562444
[No Abstract] [Full Text] [Related]
32. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.
Chalandon Y; Sbianchi G; Gras L; Koster L; Apperley J; Byrne J; Salmenniemi U; Sengeloev H; Aljurf M; Helbig G; Kinsella F; Choi G; Reményi P; Snowden JA; Robin M; Lenhoff S; Mielke S; Passweg J; Broers AEC; Kröger N; Yegin ZA; Tan SM; Hayden PJ; McLornan DP; Yakoub-Agha I;
Am J Hematol; 2023 Jan; 98(1):112-121. PubMed ID: 36266607
[TBL] [Abstract][Full Text] [Related]
33. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.
DeFilipp Z; Ancheta R; Liu Y; Hu ZH; Gale RP; Snyder D; Schouten HC; Kalaycio M; Hildebrandt GC; Ustun C; Daly A; Ganguly S; Inamoto Y; Litzow M; Szer J; Savoie ML; Hossain N; Kharfan-Dabaja MA; Hamadani M; Reshef R; Bajel A; Schultz KR; Gadalla S; Gerds A; Liesveld J; Juckett MB; Kamble R; Hashmi S; Abdel-Azim H; Solh M; Bacher U; Lazarus H; Olsson R; Cahn JY; Grunwald MR; Savani BN; Yared J; Rowe JM; Cerny J; Chaudhri NA; Aljurf M; Beitinjaneh A; Seo S; Nishihori T; Hsu JW; Ramanathan M; Alyea E; Popat U; Sobecks R; Saber W
Biol Blood Marrow Transplant; 2020 Mar; 26(3):472-479. PubMed ID: 31669399
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.
Poiré X; Artz A; Larson RA; Kline J; Odenike O; Rich E; Godley L; Stock W; van Besien K
Leuk Lymphoma; 2009 Jan; 50(1):85-91. PubMed ID: 19142796
[TBL] [Abstract][Full Text] [Related]
35. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
[TBL] [Abstract][Full Text] [Related]
36. Chronic myeloid leukemia-transplantation in the tyrosine kinase era.
Innes AJ; Apperley JF
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1037-53. PubMed ID: 25459178
[TBL] [Abstract][Full Text] [Related]
37. Comparable Outcomes of Pre- Versus Post-Tyrosine Kinase Inhibitor Era Treatment in Chronic Myeloid Leukemia: A Retrospective Cohort Study With Long-term Follow-up.
Tavakoli S; Khalaj F; Kasaeian A; Mousavi SA; Mousavian AH; Arabi F; Rad S; Rostami S; Barkhordar M; Biglari M; Mardani-Fard HA; Alemi H; Khavandgar N; Kamranzadeh Fumani H; Janbabai G; Mousavi SA; Ghavamzadeh A; Vaezi M
Cell Transplant; 2023; 32():9636897231163212. PubMed ID: 37013251
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of children with chronic myeloid leukemia: A population-based cohort study.
Egan G; Athale U; Johnston D; Pole JD; Silva M; Zorzi A; Alexander S
Pediatr Blood Cancer; 2020 Sep; 67(9):e28491. PubMed ID: 32589368
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
Ruiz-Argüelles GJ; Tarin-Arzaga LC; Gonzalez-Carrillo ML; Gutierrez-Riveroll KI; Rangel-Malo R; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Gómez-Almaguer D; Giralt S
Bone Marrow Transplant; 2008 Jul; 42(1):23-8. PubMed ID: 18612313
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of allogeneic hematopoietic stem cell transplantation in treatment of childhood myelogenous leukemia: the observation of 24 cases].
Sun Y; Sun RJ; Wei ZJ; Xiao J; Zhang YC; Gao YQ; Zhu HL
Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):813-6. PubMed ID: 23302609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
